Screener
Twist Bioscience Corporation TWST Change In Fair Value Of Contingent Consideration And Indemnity Holdback
Discontinued — last reported Q4 '25
Change In Fair Value Of Contingent Consideration And Indemnity Holdback at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Twist Bioscience Corporation in its filing.
Tagged under the XBRL concept twst:ChangeInFairValueOfContingentConsiderationAndIndemnityHoldback.
The source filing: Twist Bioscience Corporation’s 10-K, filed November 17, 2025.
- Filed
- Nov 17, 2025
- Fiscal year
- FY2025
- Accession
- 0001581280-25-000025
| (In thousands, except per share data) | Year ended September 30, 2025 | Year ended September 30, 2024 | Year ended September 30, 2023 |
|---|---|---|---|
| Research and development expenses | 80,285 | 90,852 | 106,894 |
| Selling, general and administrative expenses | 246,976 | 218,398 | 189,738 |
| Restructuring and other costs | — | — | 9,384 |
| Change in fair value of contingent considerations and holdbacks | — | — | (5,913) |
| Impairment of long-lived assets | — | 44,930 | 6,785 |
| Total costs and expenses | $512,831 | $533,805 | $462,268 |
| Loss from operations | $(136,259) | $(220,831) | $(217,159) |
| Gain on sale of business | 48,847 | — | — |
Item 8. tatements and
FAQ
- What is Twist Bioscience Corporation's change in fair value of contingent consideration and indemnity holdback?
- Twist Bioscience Corporation (TWST) reported change in fair value of contingent consideration and indemnity holdback of $0 in Q3 2025.
- What is the long-term trend for Twist Bioscience Corporation's change in fair value of contingent consideration and indemnity holdback?
- Over 4 years (2021 to 2025), Twist Bioscience Corporation's change in fair value of contingent consideration and indemnity holdback has grown at a -100.0% compound annual growth rate (CAGR), from $534K to $0.
- What does change in fair value of contingent consideration and indemnity holdback mean?
- This metric represents the periodic adjustment to the estimated liability for earn-outs or indemnity holdbacks related to business acquisitions. Changes in fair value reflect updates to management's expectations regarding the achievement of performance milestones or the resolution of indemnification claims. Fluctuations in this value impact operating expenses and provide insight into the integration and post-acquisition performance of acquired entities.
Ask your AI about Twist Bioscience Corporation's change in fair value of contingent consideration and indemnity holdback.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude